1. Targeting Tumor Vascular CD99 Inhibits Tumor Growth
- Author
-
Elisabeth J. M. Huijbers, Judy R. van Beijnum, Lena D Sialino, Arjan W. Griffioen, Inge van der Werf, Hanna A. Holland, Pia van der Laan, Anca Maria Cimpean, Victor L. Thijssen, Lisette D Faber, Hematology laboratory, Medical oncology laboratory, Radiation Oncology, and CCA - Cancer biology and immunology
- Subjects
0301 basic medicine ,lcsh:Immunologic diseases. Allergy ,MIC2 ,Endothelium ,Angiogenesis ,medicine.medical_treatment ,Lymphocyte ,CD99 ,Immunology ,Sarcoma, Ewing ,Biology ,12E7 Antigen ,Cancer Vaccines ,Metastasis ,03 medical and health sciences ,angiogenesis ,0302 clinical medicine ,Cell Line, Tumor ,medicine ,Human Umbilical Vein Endothelial Cells ,cancer ,Animals ,Humans ,Protein Splicing ,Immunology and Allergy ,Original Research ,Mice, Inbred BALB C ,Mice, Inbred C3H ,Growth factor ,medicine.disease ,vaccination ,3. Good health ,Tumor Burden ,tumor vasculature ,030104 developmental biology ,medicine.anatomical_structure ,Cancer research ,Osteosarcoma ,Female ,Sarcoma ,Endothelium, Vascular ,immunotherapy ,lcsh:RC581-607 ,030215 immunology - Abstract
CD99 (MIC2; single-chain type-1 glycoprotein) is a heavily O-glycosylated transmembrane protein (32 kDa) present on leukocytes and activated endothelium. Expression of CD99 on endothelium is important in lymphocyte diapedesis. CD99 is a diagnostic marker for Ewing's Sarcoma (EWS), as it is highly expressed by these tumors. It has been reported that CD99 can affect the migration, invasion and metastasis of tumor cells. Our results show that CD99 is also highly expressed in the tumor vasculature of most solid tumors. Furthermore, we found that in vitro CD99 expression in cultured endothelial cells is induced by starvation. Targeting of murine CD99 by a conjugate vaccine, which induced antibodies against CD99 in mice, resulted in inhibition of tumor growth in both a tumor model with high CD99 (Os-P0109 osteosarcoma) and low CD99 (CT26 colon carcinoma) expression. We demonstrated that vaccination against CD99 is safe, since no toxicity was observed in mice with high antibody titers against CD99 in their sera during a period of almost 11 months. Targeting of CD99 in humans is more complicated due to the fact that the human and mouse CD99 protein are not identical. We are the first to show that growth factor activated endothelial cells express a distinct human CD99 isoform. We conclude that our observations provide an opportunity for specific targeting of CD99 isoforms in human tumor vasculature.
- Published
- 2019
- Full Text
- View/download PDF